Lower gastrointestinal malignancy in Crohn’s disease

W R Connell, J P Sheffield, M A Kamm, J K Ritchie, P R Hawley, J E Lennard-Jones

Abstract
An increased incidence of carcinoma of the small bowel and colon has been described in patients with Crohn’s disease. Tumours arising in the rectum and anus are reported less often. Between 1940 and 1992, of some 2500 patients with Crohn’s disease seen at this hospital, 15 are known to have developed carcinoma of the lower gastrointestinal tract. Malignancy occurred in the colon in two patients, in the upper two thirds of rectum in one, in the lower third of rectum in seven, and in the anus in five. The 12 patients with carcinoma arising in the anus or lower rectum had longstanding severe anorectal Crohn’s disease, which included a stricture in four, fistula in four, proctitis in one, abscess in two, and enlarged anal skin tags in one. The development of malignancy in patients with Crohn’s disease may apply particularly to those with chronic complicated anorectal disease.

There is growing evidence from epidemiological studies and clinicopathological data obtained from case reports that Crohn’s disease is associated with an increased risk of carcinoma of the small and large bowel. In contrast with ulcerative colitis where the risk of colorectal carcinoma is clearly established, the extent of the risk in Crohn’s disease remains controversial. Four population based studies have failed to show an increase in the incidence of any type of cancer, including colorectal carcinoma, in patients with Crohn’s disease.1-3 One population study,4 a national survey of 95 American gastroenterologists,4 and three other large series from tertiary referral centres4-6 describe an increased comparative risk of colorectal cancer in patients with Crohn’s disease ranging from 2.1 to 20.0.

Three of four referral based studies have also described an increased incidence of small intestinal cancers in Crohn’s disease.4 6 The remaining report found no such excess but more gastric carcinomas were found than expected.7 In addition, there have been three long-term analyses of the overall incidence of extraintestinal cancers in Crohn’s disease and in none has an excess been found,6 8 9 although increases in squamous cell carcinomas10 11 and lymphomas11 12 have been reported.

Among the many reports of bowel tumours in Crohn’s disease, there have been few describing carcinoma of the anorectal region, anus or in association with anal or rectal fistulas.10 11 12 The risk of developing anorectal carcinoma in Crohn’s disease is unknown. Fifteen patients with carcinoma of the colon, rectum or anus have now been seen at this hospital over a 53 year period. Nine have been reported previously.11 12

This paper describes our experience of lower gastrointestinal malignancy in Crohn’s disease, and because most of the cases have arisen in the anus or lower rectum, all reports of carcinoma in these sites or associated with anal or rectal fistulas have been reviewed.

Methods
At St Mark’s Hospital, a register is maintained of all patients who have been treated for Crohn’s disease since 1940. The development of carcinoma of the large bowel or anus in any patient who continued to attend the hospital is recorded. The case notes of patients with such malignancies were reviewed. Of patients who no longer attended the hospital or in whom follow up information was unavailable, clinical details were not sought. The diagnosis of Crohn’s disease was established by clinical, radiological, endoscopic or pathological features. The histology slides of the operative specimens from those patients who had radical surgery at this hospital were reviewed. All carcinomas were within areas of Crohn’s disease or an associated anal lesion. The duration of disease was calculated from the onset of symptoms to the development of carcinoma.

Results
Two thousand four hundred and eighty patients with Crohn’s disease have been managed at this hospital over a period of 53 years. Approximately 30% of these patients have attended the hospital in the last two years. Carcinoma of the colon or anus is known not to have occurred in a further 20% of patients who had proctocolectomy or whose outcome has been previously reported as part of other research projects. Therefore, we have information regarding the presence of lower gastrointestinal malignancy in approximately 50% of our Crohn’s disease population. Fifteen patients are known to have developed 17 malignant tumours of the colon, rectum or anus over this time. Table I summarises the case details. Except for two of the squamous cell carcinomas of the anus, all tumours were diagnosed after 1966.

Two patients developed carcinoma of the colon, one had synchronous tumours of the upper two thirds of rectum, and 12 had malignancy of the lower third of rectum or anus. One patient developed a carcinoma of the anal canal 12 months after a defunctioning colostomy had been performed for intractable anal pain; in retrospect, it is probable that the tumour was already present at the time of operation (Table I: case 8). One patient with a rectal carcinoma had a defunctioning ileostomy for periods of one and 10 years: the more recent stoma had been closed 12 years before the diagnosis of cancer (Table I:
### TABLE 1  Clinical details of 15 patients with lower gastrointestinal carcinoma in Crohn's disease at one institution

<table>
<thead>
<tr>
<th>Case (ref)</th>
<th>Sex, age</th>
<th>History</th>
<th>Site CD</th>
<th>Anorectal disease</th>
<th>Symptoms</th>
<th>Past surgery</th>
<th>Axaz</th>
<th>Site ca</th>
<th>Dx ca</th>
<th>Rx ca</th>
<th>Histology</th>
<th>Stage</th>
<th>RF</th>
</tr>
</thead>
<tbody>
<tr>
<td>11316</td>
<td>F 61</td>
<td>2 mth</td>
<td>Colon, rectum</td>
<td>Nil</td>
<td>Abdominal pain, diarrhoea, diarrhoea</td>
<td>Sigmoid colon</td>
<td>Barium enema</td>
<td>LHC</td>
<td>Adenocarcinoma, adenoma</td>
<td>A</td>
<td>Dec 24 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>M 38</td>
<td>6-5 y</td>
<td>Colon</td>
<td>Nil</td>
<td>Rectal stricture 9 y</td>
<td>Anal pain, diarrhoea, RHC</td>
<td>Splenic flexure</td>
<td>Barium enema</td>
<td>SCE</td>
<td>Adenocarcinoma</td>
<td>B</td>
<td>Well 5 y</td>
<td></td>
</tr>
<tr>
<td>315</td>
<td>M 58</td>
<td>26 y</td>
<td>TI, AR</td>
<td>Rectovaginal fistula 14 y Proctitis 12 y</td>
<td>Anal pain, diarrhoea, Urgency, diarrhoea</td>
<td>IRA</td>
<td>24 mth</td>
<td>Rectum (lower)</td>
<td>Surgery</td>
<td>TPC</td>
<td>Adenocarcinoma, dysplasia</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>415</td>
<td>F 38</td>
<td>14 y</td>
<td>Colon, AR</td>
<td>Proctitis 18 y</td>
<td>Anal pain discharge, Defunctioning ileostomy (twice)</td>
<td>12 mth</td>
<td>Rectum (lower)</td>
<td>EVA</td>
<td>Surgery</td>
<td>TPC</td>
<td>Adenocarcinoma, dysplasia</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>515</td>
<td>F 46</td>
<td>18 y</td>
<td>TI, AR</td>
<td>Anal stricture 10 y</td>
<td>Anal pain, diarrhoea, Temporary colostomy, RHC, end colostomy</td>
<td>24 mth</td>
<td>Rectum (lower)</td>
<td>EVA</td>
<td>Surgery</td>
<td>Proctectomy</td>
<td>Adenocarcinoma</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>6134</td>
<td>M 58</td>
<td>32 y</td>
<td>Colon, AR</td>
<td>Proctitis 18 y</td>
<td>Anal pain discharge</td>
<td>Defunctioning ileostomy (twice)</td>
<td>12 mth</td>
<td>Rectum (lower)</td>
<td>EVA</td>
<td>Surgery</td>
<td>TPC</td>
<td>Adenocarcinoma, dysplasia</td>
<td>B</td>
</tr>
<tr>
<td>705</td>
<td>M 57</td>
<td>37 y</td>
<td>Caecum, AR</td>
<td>Proctitis 30 y, intersphincteric abscess</td>
<td>Anal pain discharge, Temporary colostomy, RHC, end colostomy</td>
<td>24 mth</td>
<td>Rectum (lower)</td>
<td>EVA</td>
<td>Surgery</td>
<td>Proctectomy</td>
<td>Adenocarcinoma in TVA, dysplasia</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>805</td>
<td>F 51</td>
<td>20 y</td>
<td>TI, AR</td>
<td>Anal stricture 10 y</td>
<td>Anal pain, diarrhoea, Temporary colostomy, RHC, end colostomy</td>
<td>24 mth</td>
<td>Rectum (lower)</td>
<td>EVA</td>
<td>Surgery</td>
<td>Proctectomy</td>
<td>Adenocarcinoma</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>9</td>
<td>F 67</td>
<td>20 y</td>
<td>TI, AR</td>
<td>Proctitis 10 y</td>
<td>Anal pain, diarrhoea, Temporary colostomy, RHC, end colostomy</td>
<td>24 mth</td>
<td>Rectum (lower)</td>
<td>EVA</td>
<td>Surgery</td>
<td>Proctectomy</td>
<td>Adenocarcinoma</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>10</td>
<td>M 51</td>
<td>20 y</td>
<td>TI, colon, rectum, rectourethral fistula,</td>
<td>Proctitis 20 y, rectourethral fistula 12 y</td>
<td>Anorexia, perianal abscess, weight loss</td>
<td>IRA</td>
<td>96 mth</td>
<td>Rectum (lower)</td>
<td>Surgery</td>
<td>Proctectomy</td>
<td>Adenocarcinoma, villous adenoma, dysplasia</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>1114</td>
<td>F 57</td>
<td>27 y</td>
<td>AR</td>
<td>Rectovaginal fistula 27 y, Anal stricture 10 y</td>
<td>Rectal bleeding, anal pain,</td>
<td>IRA</td>
<td>96 mth</td>
<td>Rectum (lower)</td>
<td>Surgery</td>
<td>Proctectomy</td>
<td>Adenocarcinoma, villous adenoma, dysplasia</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>1214</td>
<td>M 80</td>
<td>10 y</td>
<td>AR</td>
<td>Anal stricture 10 y</td>
<td>Anal pain,</td>
<td>IRA</td>
<td>72 mth</td>
<td>Anus</td>
<td>EVA</td>
<td>Local excision</td>
<td>Adenocarcinoma</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>13</td>
<td>M 41</td>
<td>13 y</td>
<td>TI, AR</td>
<td>Proctitis 10 y, rectal abscess, anal stricture + fistula 15 y</td>
<td>Anal pain, discharge, Anal lump</td>
<td>IRA</td>
<td>84 mth</td>
<td>Anus</td>
<td>EVA</td>
<td>Loop colostomy</td>
<td>Adenocarcinoma</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>14</td>
<td>F 38</td>
<td>18 y</td>
<td>AR</td>
<td>Anal tags 24 y, Anal tags 24 y</td>
<td>Painful anal tags, RHC, ileal resection</td>
<td>IRA</td>
<td>84 mth</td>
<td>Anus</td>
<td>EVA</td>
<td>Loop colostomy</td>
<td>Adenocarcinoma</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
<tr>
<td>15</td>
<td>F 53</td>
<td>24 y</td>
<td>TI, AR</td>
<td>Anal tags 24 y</td>
<td>Painful anal tags</td>
<td>IRA</td>
<td>84 mth</td>
<td>Anus</td>
<td>EVA</td>
<td>Loop colostomy</td>
<td>Adenocarcinoma</td>
<td>B</td>
<td>Dec 5 y</td>
</tr>
</tbody>
</table>

Case (ref), case number, numerals in parentheses refer to the references in which cases have been previously reported; *surgery at Royal London Hospital; age, age at diagnosis of carcinoma; M, male; F, female; history, duration of Crohn's disease; site CD, site of Crohn's disease; TI, terminal ileum; AR, anorectal; anorectal disease, nature and duration of anorectal Crohn's disease; symptoms, presenting symptom of carcinoma; RHC, right hemicolecotomy; IRA, ileorectal anastomosis; LHC, left hemicolecotomy; Axaz, treatment with azathioprine; site ca, site of carcinoma; Dx ca, method of diagnosis of carcinoma; EUA, examination under anesthetic; Rx ca, treatment carcinoma; SCE, synchronous combined excision; TPC, total proctocolectomy; chemoradioRx, chemoradiotherapy; TVA, tubulovillous adenoma; SCC, squamous cell carcinoma; stage, Duke's stage carcinoma; FU, follow up; Dec, deceased.
case 6). The patient with synchronous tumours of the upper and middle third of rectum had had a colectomy and ileorectal anastomosis 12 years previously (Table 1: case 3).

CARCINOMA OF THE COLON
The two patients with colonic cancer had symptoms of Crohn’s disease for two months and seven years before the diagnosis of carcinoma at ages of 61 and 38 years respectively. Diagnosis in each case was established by barium enema. Both specimens contained granulomas typical of Crohn’s disease in association with a predominantly mucosal pattern of inflammation in the region of the carcinoma. There was a moderately dysplastic rectal adenoma in one specimen but no other areas of dysplasia were detected. Both patients had early stage malignancies and survived more than five years.

CARCINOMA OF THE PROXIMAL TWO THIRDS OF RECTUM
A female patient aged 46 developed synchronous carcinomas of the upper and middle third of rectum 12 years after colectomy and ileorectal anastomosis had been performed for ileocolic Crohn’s disease. Moderate proctitis and a rectal stricture was present since the time of surgery and a two month course of azathioprine had been unhelpful. Elective proctectomy was undertaken because of increasing anal pain and urgency that had developed over 12 months. The operative specimen contained an invasive adenocarcinoma of the upper rectum (Dukes’s B) with adjacent high grade dysplasia and a smaller adenocarcinoma of the mid rectum arising from a villous adenoma (Dukes’s A). The intervening mucosa was inflamed in a predominantly mucosal pattern and although no distinctive features of Crohn’s disease were detected on this occasion, review of the original colectomy specimen showed the presence of granulomas. The patient has remained well for five years.

CARCINOMA OF THE LOWER THIRD OF RECTUM
Seven patients developed adenocarcinomas of the lower rectum: a synchronous carcinoma arising from a villous adenoma of the middle third of rectum occurred in one patient. Four were male and the mean age at cancer detection was 53 years. A longstanding stricture affecting the anus or rectum was present in three cases, a chronic fistula in two, a persistent abscess in one, and severe proctitis in another. The mean duration of Crohn’s disease to diagnosis of cancer was 23 years. The development of malignancy was heralded by a deterioration of symptoms in all cases; this included increasing anal pain, faecal discharge, urgency, incontinence or rectal bleeding over a 6 to 18 month period. One patient with a chronic rectourethral fistula who developed worsening perineal discomfort was subsequently found to have a carcinoma of the rectum affecting the fistulous tract (Figs 1 and 2).

Azathioprine had been given to five patients for a median duration of 24 months (range 12–96). One patient with a five year history of essential thrombocytosis was receiving hydroxyurea when cancer was diagnosed (Table 1: case 9). The tumour was found by an examination under anaesthetic in three patients; in two others this examination was negative within a year of the diagnosis of malignancy.

Of seven patients with adenocarcinoma of the lower third of rectum, the pathology specimen was available for review in six. One tumour affected a perirectal sinus, two were associated with fistulas, and three were highly invasive adenocarcinomas that disorganised the surrounding architecture. The specimen in which malignancy affected a perirectal sinus exhibited high grade dysplasia along the sinus and a concomitant carcinoma arising from a villous adenoma of the mid rectum. High grade dysplasia was also detected along the fistulous tracts of two other patients whose rectal malignancy were affected fistulas. Five of the carcinomas were mucinous. One was staged Dukes’s A, six Dukes’s B, and one Dukes’s C. All patients had surgical treatment of the tumour, which included proctectomy in five, proctocolectomy in two, and a synchronous combined excision in one. Two patients survived five years or more, four died within five years of cancer detection, and one remains alive 12 months postoperatively.

CARCINOMA OF THE ANUS
Five patients developed squamous cell carcinoma of the anal canal, one of which affected an
The remaining study, however, eight months postoperatively, two patients survived more than five years and two others remain alive six months and three years respectively after treatment for cancer. As the patient who received chemotherapy during the first period, it is premature to assess the efficacy of this treatment in anal cancer related to Crohn’s disease.

Discussion
The first reported case of colorectal carcinoma in a patient with Crohn’s disease was described by Warren and Somers in 1948. Since then, an association between the two conditions has been suggested by the clinicopathological data obtained from over 150 case reports. The extent of this association has been assessed by incidence studies comparing the risk of colon cancer in patients with Crohn’s disease with that expected in the general population. The results of these reports have differed depending on the selection of patients under analysis. Population based studies may give a more accurate assessment than referral based estimates for epidemiological reasons. Five population based studies with follow up periods ranging from 10–40 years have now been done to estimate the risk of malignancy in Crohn’s disease. Four of these have not shown an increase of any type of cancer. The remaining study, however,
showed that patients with Crohn’s disease had an increased comparative risk of colorectal cancer of 2.1 and for those with Crohn’s colitis the risk was 5.6. All four referral based studies have shown that colorectal cancers found in patients with Crohn’s disease exceeded that expected for the general population by a factor of 4.3–20.0.2–4 This variability is probably related to the entry criteria of the different studies as patients with an early onset of disease have been shown to be at greater risk of developing colorectal malignancies.5

Carcinomas of the small and large bowel in Crohn’s disease tend to occur in areas affected by underlying inflammation. Most small intestinal tumours occur in the terminal ileum; in contrast carcinoma of the duodenum or jejenum is more common in the general population.31 Hamilton found a similar anatomical distribution of 10 colorectal carcinomas occurring in areas of Crohn’s disease with 118 consecutive sporadic cancers of the large bowel.30 Most of these were situated in the left colon. In contrast, Stahl et al reported a greater number of right sided colon carcinomas in patients with Crohn’s disease than expected in the general population.32 Intestinal tumours in Crohn’s disease have been reported in association with excluded loops of bowel after bypass surgery,33 strictures,33 and internal or external fistulas.33

Considerable evidence supports a dysplasia-carcinoma sequence in Crohn’s disease.34–36 Dysplasia adjacent to colorectal carcinoma has been reported in 83–100% of cases34–36 while dysplasia distant from the cancer has been found in 23–70%.34–36 In contrast, only 2% of colectomy specimens of Crohn’s disease without carcinoma contained mild dysplasia.37 It has been suggested that the dysplasia-carcinoma sequence occurs as commonly in Crohn’s disease as in ulcerative colitis.38 The only study that has evaluated surveillance for colorectal cancer in Crohn’s disease was undertaken in 356 patients using rectal biopsies: dysplasia occurred in 5% with a predictive value for colorectal malignancy of 11%.38

More colonic carcinomas in Crohn’s disease are poorly differentiated and mucinous compared with sporadic colon malignancies30–35 and, overall, the prognosis is much poorer.35 Rectal cancer occurring in Crohn’s disease is well recognised but less attention has been given to carcinoma developing in the anal region, lower rectum or in association with anal or rectal fistulas. Only 28 such cases have been described4–12–27 and eight were reported from this hospital.13–15 A further case, without clinical details reported from the Mayo Clinic has been omitted.39 Table II summarises the details of the remaining 20. Usually, there had been a long history of anal Crohn’s disease: four patients had an anal fistula and two a rectovaginal fistula. The tumour was an adenocarcinoma in 10 patients and squamous cell cancer in five; there was one basaloid tumour, two cloacogenic cancers, and two described only as anaplastic and mucoid carcinomas respectively (Table II: cases 19 and 20). The outcome was generally poor. There is often confusion regarding the precise anatomical site where anorectal carcinomas originate. Although a tumour may seem to arise from the anus, a pathological report of adenocarcinoma tends to show that the rectum or anorectal junction was primarily affected. Conversely, a so called rectal carcinoma that contains squamous cells is more likely to have originated in the anus. It is often impossible to distinguish adenocarcinomas of the anal canal from carcinomas of the lower rectum, and at our hospital, carcinomas of the anorectal junction are grouped with carcinomas of the lower third of rectum.40 While carcinomas arising in longstanding anorectal Crohn’s disease represents a specific clinical problem, the histological distinction may have important therapeutic implications, as squamous cell carcinoma is more responsive to radiotherapy than adenocarcinoma.

Our experience with lower gastrointestinal cancer in Crohn’s disease emanates from a highly selected patient population but two features of this report deserve special comment. We feel it is appropriate to distinguish carcinomas arising from the colon and proximal rectum from those occurring in the lower third of rectum or anal canal. The number of colonic and upper rectal carcinomas was much lower than might have been expected though the reason for this remains unclear. We have satisfactory follow up on only part of our Crohn’s disease population and had the clinical outcome been pursued in the remaining patients, the number of colon or proximal rectal cancers might well have been higher. Of new patients attending our hospital with an intact gut between 1983–1990, 44% had disease confined to the colon, 33% had small and large bowel disease, and 23% small bowel disease only.42 The probability of surgery for colonic Crohn’s disease is less than 50% at 10 years at this hospital,43 which is less frequent than that reported elsewhere.44 If anything, a higher threshold for surgery is probably associated with an increased incidence of colon carcinoma. The surgical practice of bypass surgery in Crohn’s disease has however been shown and no cases of malignancy in excluded intestinal loops have been found. It is our policy to undertake endoscopic surveillance of patients with a history of colonic adenomas. Two of three patients with carcinoma of the colon or proximal rectum associated with Crohn’s disease had a concomitant adenoma and it is possible that further cases of cancer development were prevented by this surveillance practice. Histologically, the specimens of the three patients with colonic or proximal rectal tumours contained dysplasia in two cases and a predominately mucosal pattern of inflammation in all three. Because we have not systematically assessed the comparative risk of colon cancer in Crohn’s disease, we are unable to make any recommendation regarding surveillance for this malignancy in Crohn’s disease.

We do, however, wish to draw attention to the number of lower rectal and anal carcinomas that have been found. A significant proportion of patients attending this hospital with Crohn’s disease have evidence of anorectal disease and in part the experience is likely to reflect this referral pattern. The possible reasons for the development of anorectal malignancy in Crohn’s disease include chronic inflammation.
and sepsis, immunosuppressive drug use, and viral infection. Carcinomas arising in longstanding anal fistula in patients without Crohn's disease have been well described. 3,4 Three of our patients with anorectal tumours had histological evidence of malignancy affecting a fistula or sinus; another two patients with chronic perianal or perirectal fistulas developed invasive carcinomas that obliterated the normal histological architecture. Seven of our patients were treated with azathioprine for up to 84 months: this drug was used in one of the reported cases (Table II: case no. 2). 5 A higher incidence of squamous cell cancers in renal transplant recipients treated with azathioprine has been reported by Kintlen but the long-term effect of this drug in patients with Crohn's disease is not known. 6 None of the eight patients in our series tested for human papillomavirus (HPV-16) were positive for this virus. 7 Three of seven specimens of lower rectal carcinoma affected perirectal fistulas or a sinus in which dysplasia was also detected.

In conclusion, carcinomas of the lower third of rectum or anus has been a complication in 12 patients treated for Crohn's disease at St Mark's Hospital over a 53 year period and the possibility should always be borne in mind in patients with Crohn's disease affecting these areas. Many patients with anal lesions have few symptoms despite grossly distorted perianal anatomy. A recent change in symptoms may herald the onset of malignancy. Prophylactic proctectomy, however, cannot be justified in otherwise well patients, as this entails a permanent colostomy and all its disadvantages. We suggest, therefore, that patients with distal disease and chronic anal lesions be monitored regularly for dysplasia or carcinoma. This would entail frequent digital examinations and endoscopy to detect atypical ulceration, induration or stricture formation. Biopsy specimens should be examined for dysplasia. Examination under anesthetic is indicated if pain precludes Gastrointestinal examination or if an anal biopsy is required. If malignancy is suspected despite a negative examination and biopsy, the investigations should be repeated after a short period of observation. It is hoped tumours can be detected at an earlier and curable stage by this comparatively simple approach.

6 Keren HI. Carcinoma at the internal anal sphincter in Crohn's disease: results of a survey conducted by the National management. Gastroenterology 1977; 73: 723-727.
Lower gastrointestinal malignancy in Crohn's disease.

W R Connell, J P Sheffield, M A Kamm, J K Ritchie, P R Hawley and J E Lennard-Jones

Gut 1994 35: 347-352
doi: 10.1136/gut.35.3.347

Updated information and services can be found at:
http://gut.bmj.com/content/35/3/347

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Crohn's disease (932)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/